力赛生物医药科技

Lisai Biopharmaceutical is a clinical-stage biotechnology company focused on the discovery and development of innovative small molecule drugs for autoimmune and inflammatory diseases. Headquartered in Hangzhou, China, the company leverages its proprietary structure-based drug design (SBDD) platform to target high-value biological pathways with precision. Its lead candidate, LS-001, is a highly selective TYK2 inhibitor currently in Phase 1 clinical trials for the treatment of psoriasis and other immune-mediated conditions. The company's robust pipeline also includes programs targeting RORγt, NLRP3, and RIPK1, aiming to address significant unmet medical needs in the global immunology market. Backed by top-tier investors like GL Ventures and Sequoia China, Lisai Biopharmaceutical is committed to delivering next-generation oral therapies that offer improved safety and efficacy for patients.